pharma · Melanoma · Multiple Myeloma
Xijing Hospital
Xijing Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Stroke, Thyroid Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 4
- Drugs
- 5
- Patents
- 0
BCMA/CD19 Dual-Target CAR-T
Phase 1 · mab · Multiple Myeloma
BCMA/CD19 Dual-Target CAR-T for Multiple Myeloma is a Phase 1 program (mab) at Xijing Hospital with 1 ClinicalTrials.gov record(s).
Internal code PGC0008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xijing Hospital
- Phase
- Phase 1
- Modality
- mab
- Indication
- Multiple Myeloma
- Status
- active
- Trials
- 1